Clinical Trials Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Mar 28, 2023; 29(12): 1899-1910
Published online Mar 28, 2023. doi: 10.3748/wjg.v29.i12.1899
Table 1 Clinicopathological features of the patients
Item
n
% (n/n total)
Patients with suspected lesions111521.2 (115/543)
Inflammation7213.2
LGIN254.6
HGIN30.5
ESCC152.7
Suspected lesions, including non-neoplastic141-
Neoplastic lesions24531.9 (45/141)
LGIN2517.7 (25/141)
HGIN32.1 (3/141)
ESCC1712.1 (17/141)
Neoplastic lesions detected with LCI
LGIN1872.0 (18/25)
HGIN3100 (3/3)
ESCC17100 (17/17)
Neoplastic lesions detected with LCE
LGIN2184.0 (21/25)
HGIN3100 (3/3)
ESCC17100 (17/17)
Neoplastic lesions detected by different diagnosis modality
Only LCI48.9 (4/45)
Only LCE715.6 (7/45)
Both LCI and LCE3475.6 (34/45)
Neoplastic lesions per patient, mean (SD)0.08 (0.29)
Table 2 Esophageal neoplastic lesions (non-inflammation) detected using linked color imaging and Lugol chromoendoscopy
Parameter
LCI
LCE
P value
Sensitivity83.7 (36/43)90.7 (39/43)0.520
Specificity92.4 (462/500)87.0 (435/500)0.0071
PPV48.6 (36/74)37.5 (39/104)0.166
NPV98.5 (462/469)99.1 (435/439)0.549
Table 3 Clinicopathological features of neoplastic lesions (non-inflammation) detected by linked color imaging and Lugol chromoendoscopy, n (%)
Item
Detected by LCI, n = 36 patients/38 lesions
Detected by LCE, n = 39 patients/41 lesions
P value
Lesion location0.969
Upper3 (7.9)3 (7.3)
Middle11 (28.9)11 (26.8)
Lower24 (63.2)27 (65.9)
Morphologic type0.902
I1 (2.6)1 (2.4)
IIa9 (23.7)8 (19.5)
IIb18 (47.4)24 (58.5)
IIc9 (23.7)7 (17.1)
III1 (2.6)1 (2.4)
Size in mm0.814
≤ 1014 (36.8)18 (43.9)
10-203 (7.9)3 (7.3)
> 2021 (55.3)20 (48.8)
Pathology0.998
LGIN18 (47.4)21 (51.2)
HGIN3 (7.9)3 (7.3)
ESCCEP/LPM3 (7.9)3 (7.3)
MM/SM11 (2.6)1 (2.4)
≥ SM213 (34.2)13 (31.7)
Procedure time (s), median (IQR)42 (34, 50)160 (130, 189)< 0.0011